Post by: Dearbhla Kelly The infamous biannual UK and Ireland Renal SpR club meetings continue in a virtual format this weekend with a theme close to many people’s heart – ‘Keeping Going Through the Pandemic‘. Topics covered will…
On Tuesday, March 2 from 8am- 6:45pm EST, this exciting virtual conference from the National Kidney Foundation (NKF) will highlight recent major advances and best practices in the treatment and care of kidney disease, dialysis, transplantation, and organ…
The use of SGLT2 inhibitors in patients with kidney disease is becoming the standard of care. This table covers many of the common potential side effects from several of the major clinical trials. Red- difference showing more adverse…
Sodium-glucose co-transporter 2 inhibitors (SGLT2is) have emerged as a breakthrough therapy for the treatment of diabetes mellitus (DM) reducing key cardiovascular and kidney endpoints. These effects appear to be independent of their effects on blood pressure and glucose….
In April of this year, the highly-anticipated CREDENCE Trial was presented (and live-streamed) at the International Society of Nephrology (ISN) World Congress of Nephrology in Australia and simultaneously published in NEJM. But before we start dusting off our…
